Highlights Newsletter 3

This newsletter presents you the following key sessions:

1. PODCAST with dr. Banerjee about the impact of COVID-19 on oncology professionals

2. Post-operative conformal radiotherapy not recommended for all patients with completely resected
    non-small cell lung cancer and mediastinal N2 involvement

3. Pembrolizumab plus chemotherapy: a new standard of care in the first-line treatment of advanced
    oesophageal cancer

4. Manageable safety profile and preliminary evidence of efficacy of the bispecific T-cell engager AMG 160
    in metastatic castration-resistant prostate cancer

5. No survival benefit with pegylated liposomal doxorubicin and trabectedin followed by platinum at
    progression for patients with recurrent ovarian cancer